

EUROPEAN MEETING ON HIV & HEPATITIS 2022

TREATMENT
STRATEGIES &
ANTIVIRAL DRUG
RESISTANCE

PARIS, FRANCE
8 - 10 JUNE 2022



Program Book

2003 | 1st | HIV
Luxembourg, Luxembourg

2004 | 2nd | HIV
Rome, Italy

2005 | 3rd | HIV
Athens, Greece


2006 | 4th | HIV
Monte Carlo, Monaco

2007 | 5th | HIV
Cascais, Portugal

2008 | 6th | HIV
Budapest, Hungary

2009 | 7th | HIV
Stockholm, Sweden

2010 | 8th | HIV
Sorrento, Italy



Paris
2022

Luxembourg
2003

Budapest
2008

Monte Carlo
2006

Barcelona
2012
2014
2015

Cascais
2007

Rome
2004
2013
2016
2017
2018
2019

Sorrento
2010

Athens
2005

Paphos
2011



2011 | 9th | HIV & Hepatitis
Paphos, Cyprus

2012 | 10th | HIV & Hepatitis
Barcelona, Spain

2013 | 11th | HIV & Hepatitis
Rome, Italy

2014 | 12th | HIV & Hepatitis
Barcelona, Spain

2015 | 13th | HIV & Hepatitis
Barcelona, Spain

2016 | 14th | HIV & Hepatitis
Rome, Italy

2017 | 15th | HIV & Hepatitis
Rome, Italy

2018 | 16th | HIV & Hepatitis
Rome, Italy

2019 | 17th | HIV & Hepatitis
Rome, Italy

2020 | 18th | HIV & Hepatitis
Virtual

2021 | 19th | HIV & Hepatitis
Virtual

2022 | 20th | HIV & Hepatitis
Paris, France | Venue: Hyatt Regency Paris Etoile



| | |
|---|----|
| Welcome | 5 |
| Practical Information | 6 |
| Accreditation | 7 |
| Program Committee & Organizing Committee | 8 |
| Scientific Committees & Our Team | 9 |
| Speakers | 10 |
| Program | 12 |
| Acknowledgments | 18 |





Celebrating **20 Years** of **HIV & Hepatitis** Research and Treatment



Dear delegates,

We are very pleased to welcome you to the **20th anniversary** of the **European Meeting on HIV and Hepatitis: Treatment Strategies and Antiviral Drug Resistance**. It is also a great pleasure to welcome you to Paris and meet you in person - making this event a sociable one again! This year's edition will take place for the first time in a hybrid setting.

The **European Meeting on HIV and Hepatitis** is the premier European platform for clinicians, allied healthcare providers, researchers, and clinical virologists to discuss the latest developments in antiviral therapy for HIV, HCV, HBD, and HDV and translate them into new treatment strategies to further improve clinical care.

Founded twenty years ago as the European HIV resistance workshop, this meeting has evolved to embrace all aspects of clinical care for people living with HIV and viral hepatitis in Europe. This year, the meeting will also include a full-day program on clinical virology, molecular epidemiology, and public health aspects of SARS-CoV-2 in Europe.

In the last decade, the European Meeting on HIV and Hepatitis has been able to capture leading clinicians, virologists, and researchers from the different regions of Europe. As such, this meeting is the only European platform where clinical virologists get together on an annual basis to present their latest results and discuss the clinical management of HIV, Viral Hepatitis, and COVID-19.

We are excited to welcome you virtually or in Paris!

On behalf of the Organizing Committee,

Anne-Geneviève Marcelin
Slim Fourati

Workshop Chairs

Program Chairs



**Anne-Geneviève
Marcelin,
MD**

Hôpital Pitié-Salpêtrière Paris,
France



**Slim Fourati,
MD, PhD**

Henri Mondor Hospital, Paris-
Est University, France



Abstracts

Accepted abstracts are published in *Reviews in Antiviral Therapy & Infectious Diseases, Volume 2022_3*.

Badge Policy

All registered delegates are provided with a badge. Admission is restricted to registered participants wearing their name badges.

Please wear your badge at all times to ensure admission to the sessions. No spare badges can be issued.

Certificate of Attendance

The certificate of attendance will be sent by e-mail after completion of the post-meeting survey.

Feedback

Your feedback is valuable to us and enables us to further improve this meeting. After each day, a survey will be sent to you via email. We would like to ask you to complete it.

Networking

In-Person

Make use of the options to network during the coffee breaks, lunches, welcome reception, and networking dinner.

The networking dinner is for registered delegates only. Contact the onsite team if you would like to purchase a ticket.

Virtually

The Meeting Hub allows you to connect and communicate with other attendees. Once you have located an attendee you want to connect with, click the Connect button. Once the other attendee accepts your request, you can choose to interact by starting a live chat or live video call. You can also schedule a meeting at a later time, send messages, and take notes. Contact information for all attendees you have connected with will be included when you export contacts.

Notes

You will be able to take notes during the meeting. Any notes that you take throughout the event can be exported by selecting the Export icon on the top right of the screen near your Profile image.

Posters

During the meeting, all accepted posters are displayed in the virtual Poster Gallery. The Poster Gallery is always open for you.

For those attending in-person, there will be a **Poster Viewing Session** at the end of Day 1, Wednesday, 8 June 2022 at 17:30 CEST and two parallel **Guided Poster Tours** in the coffee break on Day 3, Friday 10 June 2022 at 10:05 CEST

Presentations and Webcasts

ame Webcasts of the presentations along with the PDF presentations will be available on www.AcademicMedicalEducation.com 3 weeks after the meeting. You will be able to watch the presentations on the virtual portal until 3 weeks after the meeting.

Social Media

We encourage you to post news and tweet about **#EUHIVHEP** on your social media accounts during the workshop.

You can either post your own tweets using the hashtag **#EUHIVHEP** or retweet a message from the official [@Academic_MedEdu](https://twitter.com/Academic_MedEdu).

Time Zones

Times are in Central European Summer Time (CEST). If you need to convert the times to your timezone, this website might be of interest to you: www.worldtimebuddy.com

Venue

The European Meeting on HIV & Hepatitis 2022 will be held at the Hyatt Regency Paris Étoile in Paris, France. To attend in person, you must have an "in-person registration".

Virtual Platform

OnAIR is the virtual platform that will be used for the European Meeting on HIV & Hepatitis 2022 for those attending virtually. This is also where the recordings will be located until 3 weeks after the meeting.

A video tutorial on how to use the portal can be found [here](#).

Disclaimer: This meeting aims to offer participants the opportunity to share information. Virology Education cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the meeting.



Get Your ECMEC®s



The **20th European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance** Paris, France, 08/06/2022-10/06/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **15 European CME credits (ECMEC®s)**.

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

You will receive your certificate of attendance with the credit upon completion of the post-meeting survey.



Program Committee



Francesca Ceccherini-Silberstein, PhD

University of Rome "Tor Vergata", Italy

[View Bio >](#)



Slim Fourati, MD, PhD

Henri Mondor Hospital, Paris-Est University, France

[View Bio >](#)



Stephan Dressler, MD, PhD

Freie Universitaet Berlin, Germany

[View Bio >](#)



Anne-Geneviève Marcelin, MD

Hôpital Pitié-Salpêtrière Paris, France

[View Bio >](#)



Dimitrios Paraskevis, PhD

National and Kapodistrian University of Athens, Greece

[View Bio >](#)



Roger Paredes, MD, PhD

Hospital Germans Trias i Pujol / IrsiCaixa AIDS Research Institute, Spain

[View Bio >](#)



Jonathan Schapiro, MD

National Hemophilia Center, Sheba Medical Center, Israel

[View Bio >](#)

Organizing Committee



Stéphane Chevaliez, PharmD, PhD

University of Paris-Est Creteil, France

[View Bio >](#)



Carlo Federico Perno, MD, PhD

Pediatric Hospital Bambino Gesù, Italy

[View Bio >](#)



Anne-Mieke Vandamme, PhD

University of Leuven, Belgium

[View Bio >](#)



Linos Vandekerckhove, MD, PhD

Ghent University Hospital, Belgium

[View Bio >](#)



Annemarie Wensing, MD, PhD

University Medical Center Utrecht, the Netherlands

[View Bio >](#)

Scientific Committee

Marina Bobkova, PhD

Ivanovsky Institute of Virology, Russia

Rolf Kaiser, PhD

University of Cologne, Germany

Leon Kostrikis, PhD

University of Cyprus, Cyprus

Clive Loveday, PhD

ICVC Charitable Trust, Clinical Virology, United Kingdom

Monique Nijhuis, PhD

University Medical Centre Utrecht, the Netherlands

Milosz Parczewski, MD, PhD

Pomeranian Medical University, Poland

Mario Poljak, MD, PhD

Institute for Microbiology and Immunology, Slovenia

Gary Rubin, MD

University of Toronto, Canada

Maria Santoro, MD

University of Rome "Tor Vergata", Italy

Anders Sönnerborg, MD, PhD

Karolinska Institute, Sweden

Janusz Stanczak, PhD

University of Warsaw, Poland

Jens Verheyen, MD, PhD

Institute of Immunology and Genetics, Germany

David van de Vijver, PharmD, PhD

Erasmus University Rotterdam, the Netherlands

Hauke Walter, MD

Medizinisches Labor Stendhal, Germany

Maurizio Zazzi, PhD

University of Siena, Italy

Our Team



Jesper Niesen

Project Manager

Jesper.Niesen@amededu.com



Paula Janiak

Junior Project Manager

Paula.Janiak@amededu.com

Speakers



**Jan Albert,
MD, PhD**

Karolinska Institute,
Sweden

[View Bio >](#)



**Tarik Asselah,
MD, PhD**

Université de Paris,
France

[View Bio >](#)



**Christian Callebaut,
PhD**

Gilead Sciences,
United States

[View Bio >](#)



**Rafael Campo,
MD**

MSD,
United States

[View Bio >](#)



**Simon Cauchemez,
PhD**

Pasteur Institute,
France

[View Bio >](#)



**Nicolas de Prost,
MD, PhD**

Henri Mondor Hospital, Assistance Publique-
Hôpitaux de Paris Est Créteil,
France

[View Bio >](#)



**Federico García,
PharmD, PhD**

Hospital Universitario San Cecilio,
Spain

[View Bio >](#)



**Harmony Garges,
MD, MPH**

ViiV Healthcare,
United Kingdom

[View Bio >](#)



**Anna Maria Geretti,
MD, PhD, FRCPATH**

University of Rome / King's College
London,
Italy / United Kingdom

[View Bio >](#)



**Pierre-Marie Girard,
MD, PhD**

Centre Hospitalier-Universitaire St Antoine,
Paris / University Pierre et Marie Curie,
France

[View Bio >](#)



**Enrico Girardi,
MD**

Istituto Nazionale Malattie Infettive
"L. Spallanzani" (IRCCS),
Italy

[View Bio >](#)



**Jérémie Guedj,
PhD**

Inserm and Université de Paris,
France

[View Bio >](#)



**Stéphane Hué,
MSc, PhD**

London School of Hygiene &
Tropical Medicine,
United Kingdom

[View Bio >](#)



**David Jilich,
MD**

Hospital Na Bulovce,
Czech Republic

[View Bio >](#)



**Daniel Kuritzkes,
MD**

Brigham and Women's Hospital;
Harvard Medical School,
United States

[View Bio >](#)



**Karine Lacombe,
MD, PhD**

Hôpital Saint Antoine Paris,
France

[View Bio >](#)



**Brett Leav,
MD**

Moderna,
United States

[View Bio >](#)



**Jean-Daniel Lelièvre,
MD, PhD**

Henri Mondor University Hospital,
France

[View Bio >](#)



**Thibault Mesplède,
MSc, PhD**

Erasmus Medical Centre,
the Netherlands

[View Bio >](#)



**George Papatheodoridis,
MD, PhD**

Medical School of National &
Kapodistrian University of Athens,
Greece

[View Bio >](#)



**Olivier Schwartz,
PhD**

Pasteur Institute,
France

[View Bio >](#)



**Guido Silvestri,
MD**

Emory University School of Medicine,
United States

[View Bio >](#)



**Valentina Svicher,
PhD**

University of Rome "Tor Vergata",
Italy

[View Bio >](#)



Wednesday, 8 June 2022

Time Zone: Central European Summer Time (CEST)

| | | | |
|------------------|--|---------------------------|----|
| 8:00 | Registration | | |
| | Opening of the Meeting <i>Chairs: Anne-Geneviève Marcelin & Slim Fourati</i> | | |
| 9:00 | Opening Words Anne-Geneviève Marcelin, MD Hôpital Pitié-Salpêtrière Paris, France Slim Fourati, MD, PhD Henri Mondor Hospital, Paris-Est University, France | | |
| Session 1 | SARS-CoV-2: Viral Evolution and Its Impact <i>Chairs: Anne-Geneviève Marcelin & Slim Fourati</i> | | |
| 9:15 | Origin and Evolution of SARS-CoV-2 Dimitrios Paraskevis, PhD National and Kapodistrian University of Athens, Greece | | |
| 9:40 | Impact of Variants on Clinical Presentation and Outcome in Severe COVID Disease Nicolas de Prost, MD, PhD Henri Mondor University Hospital, France | | |
| 10:05 | COVID-19 Vaccines: Correlates Protection - T Cell Response - Immunogenicity - Booster - Ag Levels Olivier Schwartz, PhD Institut Pasteur, France | | |
| 10:30 | Roundtable Discussion | | |
| 10:45 | Coffee & Networking Break | | |
| Session 2 | COVID-19 Therapeutics <i>Chairs: Jonathan Schapiro & Anna Maria Geretti</i> | | |
| 11:15 | Early Clinical Phase - Monoclonal Antibodies Roger Paredes, MD, PhD IrsiCaixa AIDS Research Institute, Spain | | |
| 11:40 | Early Clinical Phase - Antiviral Drugs Daniel Kuritzkes, MD Brigham and Women's Hospital; Harvard Medical School, United States | | |
| 12:05 | Roundtable Discussion | | |
| | Special Lecture | | |
| 12:30 | Current Outbreaks of Concern Federico García, PharmD, PhD Hospital Universitario San Cecilio, Spain | | |
| 13:00 | Lunch | | |
| Session 3 | SARS-CoV-2: Impact of Variants <i>Chairs: Roger Paredes & Linos Vandekerckhove</i> | | |
| 14:00 | Characterization of SARS-CoV-2 Epidemic and Transmission Dynamics in Children Over the Four COVID-19 Waves | Rossana Scutari, Italy | #1 |



Wednesday, 8 June 2022

Time Zone: Central European Summer Time (CEST)

| | | | |
|------------------|---|---------------------------------|----|
| 14:10 | Circulation of SARS-CoV-2 Variants in Central Italy: Spike Variability Characterization by Deep-Sequencing | Maria Concetta Bellocchi, Italy | #2 |
| 14:20 | SARS-CoV-2 Mutations and Variants May Muddle the Sensitivity of COVID-19 Diagnostic Assays | Mohammad Alkhatib, Italy | #3 |
| 14:30 | Seroprevalence of SARS-CoV-2 Infection and Evolution of Humoral Immune Response in PLWHIV in the Ile-de-France Area | Basma Abdi, France | #4 |
| 14:40 | Impact of SARS-CoV-2 Omicron and Delta Sub-Lineage AY.4.2 Variant on Neutralization by Sera of Patients Treated With Different Licensed Monoclonal Antibodies | Lia Fiaschi, Italy | #5 |
| 14:50 | Levels and Durability of Humoral and T-Specific Responses After the Booster Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility | Annalisa Bergna, Italy | #6 |
| 15:00 | Q&A | | |
| 15:15 | Coffee & Networking Break | | |
| Session 4 | Public Health Response to the Pandemic <i>Chairs: Slim Fourati & Stephan Dressler</i> | | |
| 15:45 | Impact of Covid Pandemic on HIV Epidemiology and Cascade of Care in Europe Anna Maria Geretti, MD, PhD, FRCPath University of Rome, Italy / King's College London, United Kingdom | | |
| 16:10 | Country Experiences: Western Europe / France Simon Cauchemez, PhD Pasteur Institute, France | | |
| 16:20 | Country Experiences: Eastern Europe / Czech Republic David Jilich, MD Hospital Na Bulovce, Czech Republic | | |
| 16:30 | Country Experiences: Northern Europe / Sweden Jan Albert, MD, PhD Karolinska Institute, Stockholm, Sweden | | |
| 16:40 | Country Experiences: Southern Europe / Italy Enrico Girardi, MD Istituto Nazionale Malattie Infettive "L. Spallanzani" - IRCCS | | |
| 16:50 | Roundtable Discussion: What Have We Learned and Are We Ready for the Next Pandemic? | | |
| | Andrea De Luca Lecture | | |
| 17:15 | The Top 10 Important Observations Last Year Linos Vandekerckhove, MD, PhD Ghent University Hospital, Belgium | | |
| 17:45 | Welcome Reception & Poster Viewing | | |

Thursday, 9 June 2022

Time Zone: Central European Summer Time (CEST)

| | | | |
|--|---|---|-----|
| Session 5 | | | |
| Clinical Management of HIV Patients | | | |
| <i>Chairs: Daniele Armenia & Josep Llibre</i> | | | |
| 8:30 | Implementing LA-ARVs in Europe: Which Patient? Which Formulation? Pierre-Marie Girard, MD, PhD Centre Hospitalier-Universitaire St Antoine, Paris; University Pierre et Marie Curie | | |
| 8:55 | New Antiretroviral Compounds: What Are the Resistance Concerns? Anne-Geneviève Marcelin, MD Hôpital Pitié-Salpêtrière Paris, France | | |
| 9:20 | Transmitted Drug Resistance to Integrase Based First-Line Treatment in Europe, 2018-2021 | Federico García, Spain | #7 |
| 9:30 | HIV Transmission Clusters in Europe: A Perspective View of Late Presenters and Non-Late Presenters | Mafalda N. S. Miranda, Portugal | #8 |
| 9:40 | HIV-1 Transmitted Drug Resistance and Transmission Clusters in Newly Diagnosed Patients in Portugal Between 2014 and 2019 | Marta Pingarilho, Portugal | #9 |
| 9:50 | Reaching the 95-95-95 Targets Will Not Eliminate HIV Transmission in 2030 Among Individuals Born in Sub-Saharan Africa Residing in the Netherlands | Shreoshee Mukherjee, the Netherlands | #10 |
| <hr/> | | | |
| 10:00 | Roundtable Discussion | | |
| <hr/> | | | |
| 10:20 | Coffee Break | | |
| <hr/> | | | |
| Session 6 | | | |
| New Markers / Technologies in Virology (Diagnostics) - What the Lab Can Offer | | | |
| <i>Chairs: Anne-Mieke Vandamme & Rolf Kaiser</i> | | | |
| 10:50 | HIV Reservoir Quantification by Combining Tota HIV-1 DNA Assay and Intact Proviral DNA Assay (IPDA) in One Triplex Digital PCR Reaction | Mareva Delporte, Belgium | #11 |
| | The Evaluation of a 5-Plex "Rainbow" Digital PCR Assays to Measure Intact HIV-1 Proviral DNA | Mareva Delporte, Belgium | #12 |
| 11:05 | Temporal Trend of Drug-Resistance and APOBEC Editing in PBMC Genotypic Resistance Tests From HIV-1 Infected Virologically Suppressed Individuals | Daniele Armenia, Italy | #13 |
| <hr/> | | | |
| 11:15 | Q&A | | |
| <hr/> | | | |



Thursday, 9 June 2022

Time Zone: Central European Summer Time (CEST)

Let's Talk About Resistance Barriers: How Can Clinicians Work Towards Treatment Optimisation?

Chair: Anne-Geneviève Marcelin

- 11:35 **Welcome and Introduction**
Anne-Geneviève Marcelin, MD
Hôpital Pitié-Salpêtrière Paris, France
- 11:40 **In the Era of 2nd Generation Oral Integrase Inhibitors, What Is Treatment Optimisation?**
Anne-Geneviève Marcelin, MD
Hôpital Pitié-Salpêtrière Paris, France
- What Do We Know About the Development of Resistance with 2nd Generation Integrase Inhibitor-Based Regimens?**
Anne-Geneviève Marcelin, MD
Hôpital Pitié-Salpêtrière Paris, France
- 11:55 **What Is Meant by High Barrier to Resistance, and Forgiveness?**
Thibault Mesplède, MSc, PhD
Erasmus Medical Centre, the Netherlands
- What Do We Need to Know About M184V?**
Thibault Mesplède, MSc, PhD
Erasmus Medical Centre, the Netherlands
- 12:15 **What Are the Data from Clinical Studies and Real-World Cohorts Telling Us?**
Karine Lacombe, MD, PhD
Hôpital Saint Antoine Paris, France
- 12:30 **Summary and Close**
Anne-Geneviève Marcelin, MD
Hôpital Pitié-Salpêtrière Paris, France

12:35 Lunch

Session 7 What's in the HIV Pipeline?

Chair: Jonathan Schapiro

- 13:30 **ViiV**
Harmony Garges, MD, MPH
Senior Vice President, Chief Medical Officer and Head of Global Medical, ViiV Healthcare, United Kingdom
- 13:45 **Gilead**
Christian Callebaut, PhD
Senior Director at Gilead Sciences, United States
- 14:00 **MSD**
Rafael Campo, MD
MSD, United States
- 14:15 **Moderna**
Brett Leav, MD
Head, Clinical Development, Public Health Vaccines at Moderna, United States
- 14:30 **Roundtable Discussion**

Thursday, 9 June 2022

Time Zone: Central European Summer Time (CEST)

| | | | |
|--|--|--|-----|
| Session 8 HIV-Related Abstract Presentations <i>Chairs: Miłosz Parczewski & Gary Rubin</i> | | | |
| 14:45 | Comparison of Markers of Inflammation and Associated Baseline Variables in Virologically Suppressed Participants in the TANGO Study at Week 144 | Ruolan Wang, United States | #14 |
| 14:55 | HIV-1 Integrase Resistance Associated Mutations and the Use of Dolutegravir in Sub-Saharan Africa: A Systematic Review and Meta-Analysis | Ezechiel Ngoufack Jagni Semengue, Cameroon | #15 |
| 15:05 | Predictors of Integrase Resistance in Individuals Who Failed a Regimen Containing Dolutegravir in French and Italian Clinical Settings | Daniele Armenia, Italy | #16 |
| 15:15 | Evaluation of the Virological Efficacy of Switching To Dolutegravir-Based Tritherapy in Patients Followed Under Real-Life Condition in Abidjan, Côte d'Ivoire | Jean-Jacques Renaud Dechi, Côte d'Ivoire | #17 |
| 15:25 | Major Protease Resistance in West African HIV-1 Subtypes Is Associated With Novel Protease Mutations and Accelerated gag Evolution During Second-Line ART | Kate El Bouzidi, United Kingdom | #18 |
| 15:35 | Interpretation of the T66I and G118R Mutations in Integrase in HIV-2 | Jeroen Van Kampen, the Netherlands | #19 |
| 15:45 | Q&A | | |
| 16:00 | Coffee & Networking Break | | |
| Session 9 Vaccine Development <i>Chair: Annemarie Wensing</i> | | | |
| 16:30 | Update on HIV Vaccines Guido Silvestri, MD Emory University School of Medicine, United States | | |
| 16:55 | Response to Vaccination in People Living with HIV: COVID-19, Hep B, HPV Jean-Daniel Lelièvre, MD, PhD Henri Mondor University Hospital, France | | |
| 17:20 | Roundtable Discussion | | |
| Charles Boucher Lecture | | | |
| 17:35 | Twenty Years of HIV Research in Europe Annemarie Wensing, MD, PhD University Medical Center Utrecht, The Netherlands | | |
| 18:00 | End of Day 2 | | |
| 19:00 | Networking Dinner (for registered delegates only) | | |



Friday, 10 June 2022

Time Zone: Central European Summer Time (CEST)

Session 10 Update on HCV / HBV

Chairs: Francesca Ceccherini-Silberstein & Valentina Svicher

- 8:30 **Viral Load Kinetics During Treatment: HBV (Novel Markers) - Modelling /Scientific**
Jérémie Guedj, PhD
Inserm and Université de Paris, France
- 8:55 **Progress Towards Elimination Goals for Viral Hepatitis?**
Tarik Asselah, MD, PhD
Université de Paris, France
- 9:20 Virological Characterization of Treatment Failures and Retreatment Outcomes in Patients Infected With “Unusual” HCV Genotype 1 Subtypes Erwan Vo Quang, France #20
- 9:30 The Acquisition of Positively Charged Amino Acids In HBsAg C-Terminus Impairs HBsAg Secretion, Affects Its Structural Stability and Is Associated With HBV-Induced Liver Cancer Lorenzo Piermatteo, Italy #21
- 9:40 HBcrAg Tightly Correlates With Elevated HDV Replicative Activity and With Enhanced Liver Inflammation and Damage: Role of HBcrAg as a Biomarker of Liver Disease Progression in the Setting of HDV Co-Infection Stefano D’Anna, Italy #22

9:50 Roundtable Discussion

10:05 Coffee Break & Guided Poster Tours

Session 11 Challenges and Opportunities in Hepatitis D: Epidemiology, Diagnosis, and Treatment

Chairs: Tarik Asselah & Slim Fourati

- 11:00 **HDV Origin & Epidemiology**
Stéphane Hué, MSc, PhD
London School of Hygiene & Tropical Medicine, United Kingdom
- 11:25 **HDV Diagnostic Approaches**
Valentina Svicher, PhD
University of Rome “Tor Vergata”, Italy
- 11:50 **New Therapeutics for HBV/HDV Treatments**
George Papatheodoridis, MD, PhD
Medical School of National & Kapodistrian University of Athens, Greece

12:15 Roundtable Discussion

Closure of the Meeting

Chairs: Anne-Geneviève Marcelin & Slim Fourati

- 12:30 **Closing Words including the Ricardo Camacho Award**
Anne-Geneviève Marcelin, MD
Hôpital Pitié-Salpêtrière Paris, France
Slim Fourati, MD, PhD
Henri Mondor Hospital, Paris-Est University, France

12:45 End of the Meeting

GOLD LEVEL SPONSOR



SILVER LEVEL SPONSOR



Supported by Gilead who provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.

ENDORSERS



ACADEMIC PARTNERS



This symposia is intended for
HEALTHCARE PROFESSIONALS ONLY
NX-GBL-HVX-ADVT-220003, May 2022

**UNTIL
FEAR
BECOMES**

HOPE

**ViiV Healthcare. Here until HIV and AIDS are not.
Find out more at viivhealthcare.com**

Join us for a ViiV-sponsored scientific symposium
on Thursday 9th June 11:35–12:35 (CEST)

**Let's Talk About Resistance Barriers:
How Can Clinicians Work Towards
Treatment Optimisation?**

Speakers and location to be confirmed

#WeWontStop

ViiV
Healthcare

